Strong sales growth in its radiopharmaceutical segment contributed to a 2% increase in sales for isotope technology developer Eckert & Ziegler in the first half of 2016.
For the period (end-30 June), Eckert & Ziegler had sales of 70.1 million euros, up from 69 million euros in the first half of 2015. In first-half highlights, radiopharma segment sales reached 19.4 million euros, up 12% from the 17.3 million euros reported in the same period a year ago.
The company's isotope products segment produced 40.2 million euros in sales, up 4% from the 38.8 million euros recorded in the first half of 2015. On the downside, the radiation therapy segment accounted for sales of 12 million euros, down 18% from the 14.7 million euros produced last year.
Eckert & Ziegler had first-half net income of 4.8 million euros, down from 7.2 million euros a year ago. The expected decline was largely attributable to a drop in extraordinary income of nearly 6.0 million euros.
Looking ahead, the company said it expects to have more or less constant sales of 140 million euros in 2016, with profit declining to around 1.80 euros per share.
